GLP-1s: what is behind the variation in efficacy? Researchers are trying to untangle the roles of genetics, access and treatment persistence in the efficacy of GLP-1s. As evidence suggests, weight-loss outcomes are different between patient groups.…
UK study to look at semaglutide for alcohol addiction and obesity The four-year trial will aim to help “guide future care” for alcohol-related liver disease and obesity in the UK.…
Survey warns of ‘lifestyle drive’ for weight-loss medication A LloydsPharmacy Online Doctor-commissioned survey found that an upcoming wedding is the most common motivator for patients to use or consider weight-loss medication.…
Test your knowledge of medicines safety Our self-assessment quiz covers the principles of medicines safety and some scenarios that pharmacists might encounter in daily practice.…
MHRA approves orforglipron weight-loss pill The Medicines and Healthcare products Regulatory Agency said its approval of orforglipron makes the UK the first country in Europe to authorise the medication.…
UK patients being recruited for ribupatide trials Researchers will assess the efficacy of up to 10mg doses of weight-loss drug ribupatide in patients with or without diabetes over around an 18-month period.…
Incretin-based weight-loss drugs should not be deliberately continued in pregnancy, consensus guidelines state The guidelines have been drawn up by a multidisciplinary group of experts following a systematic scoping review.…
Around one in five adults would share weight-loss jabs with friends, survey finds A Pharmacy2U-commissioned survey also found that more than one-quarter of UK adults said that they would share oral weight-loss medication with friends or family.…
Switching between weight-loss medications This article proposes practical approaches for safe, effective switching between tirzepatide and semaglutide.…
Novo Nordisk sues Eli Lilly over ‘misleading’ GLP-1 advertising Novo Nordisk claims that Lilly’s advertising campaigns intentionally used outdated studies to offer “proof of broad, product-level superiority” of its Zepbound and Mounjaro products over Novo Nordisk’s Wegovy and Ozempic products.…
